DK2968461T3 - Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf - Google Patents

Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK2968461T3
DK2968461T3 DK14722439.8T DK14722439T DK2968461T3 DK 2968461 T3 DK2968461 T3 DK 2968461T3 DK 14722439 T DK14722439 T DK 14722439T DK 2968461 T3 DK2968461 T3 DK 2968461T3
Authority
DK
Denmark
Prior art keywords
pdgf
methods
fusion proteins
binding portions
vegf binding
Prior art date
Application number
DK14722439.8T
Other languages
English (en)
Inventor
Jeffery Ardinger
Samuel Wadsworth
Abraham Scaria
Peter Pechan
Hillard Rubin
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK2968461T3 publication Critical patent/DK2968461T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
DK14722439.8T 2013-03-13 2014-03-13 Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf DK2968461T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780914P 2013-03-13 2013-03-13
PCT/US2014/026872 WO2014160507A1 (en) 2013-03-13 2014-03-13 Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof

Publications (1)

Publication Number Publication Date
DK2968461T3 true DK2968461T3 (da) 2022-12-19

Family

ID=50680144

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14722439.8T DK2968461T3 (da) 2013-03-13 2014-03-13 Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf

Country Status (27)

Country Link
US (4) US9637534B2 (da)
EP (1) EP2968461B1 (da)
JP (2) JP6561042B2 (da)
KR (1) KR102228921B1 (da)
CN (1) CN105188733B (da)
AR (1) AR095437A1 (da)
AU (2) AU2014243712B2 (da)
BR (1) BR112015022208A8 (da)
CA (1) CA2904623A1 (da)
DK (1) DK2968461T3 (da)
ES (1) ES2933558T3 (da)
FI (1) FI2968461T3 (da)
HK (1) HK1220618A1 (da)
HR (1) HRP20221447T1 (da)
HU (1) HUE060464T2 (da)
IL (2) IL240950B (da)
LT (1) LT2968461T (da)
MX (1) MX363533B (da)
PL (1) PL2968461T3 (da)
PT (1) PT2968461T (da)
RS (1) RS63820B1 (da)
RU (1) RU2692652C2 (da)
SG (3) SG10201707501TA (da)
SI (1) SI2968461T1 (da)
TW (1) TWI631133B (da)
UY (1) UY35407A (da)
WO (1) WO2014160507A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
DK2968461T3 (da) 2013-03-13 2022-12-19 Genzyme Corp Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf
US20160137717A1 (en) * 2013-06-20 2016-05-19 Gabriela Burian Use of a vegf antagonist in treating choroidal neovascularisation
SI3041513T1 (sl) 2013-09-08 2020-11-30 Kodiak Sciences Inc. Zwitterionski polimerni konjugati faktorja VIII
KR101819135B1 (ko) 2014-03-18 2018-01-18 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질
AU2015279560B2 (en) * 2014-06-28 2020-09-17 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
MX2017008643A (es) * 2015-03-11 2018-04-26 Allgenesis Biotherapeutics Inc Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf).
BR112017027567A2 (pt) * 2015-06-28 2018-09-04 Allgenesis Biotherapeutics Inc. proteínas de fusão para inibir a angiogênese
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
EP3436484A4 (en) 2016-03-30 2019-12-04 AB Biosciences, Inc. RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND METHODS OF MAKING AND USING THEM
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
JP6849390B2 (ja) * 2016-10-28 2021-03-24 花王株式会社 関節のこわばり改善剤
WO2019083171A2 (ko) * 2017-10-26 2019-05-02 주식회사 큐로진생명과학 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물
KR102205830B1 (ko) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
US11548931B2 (en) 2017-11-16 2023-01-10 Xl-Protein Gmbh PASylated VEGFR/PDGFR fusion proteins and their use in therapy
WO2019147944A1 (en) * 2018-01-26 2019-08-01 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disordres using anti-vegf agents
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
US20230024569A1 (en) * 2019-12-04 2023-01-26 Cdmogen Co., Ltd. Composition for treating diabetic retinopathy, comprising raav containing soluble vegfr-1 variant cdna
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN113105558A (zh) * 2021-04-01 2021-07-13 芜湖英特菲尔生物制品产业研究院有限公司 一种酿酒酵母表达人rPDGF-HSA融合蛋白及其标准品的制备方法
JP2024525186A (ja) * 2021-06-18 2024-07-10 イカロベック リミテッド 網膜障害
WO2023199951A1 (ja) * 2022-04-13 2023-10-19 株式会社セルージョン 抗ｖｅｇｆ機能を有する多能性幹細胞及びその分化細胞
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
KR20240019034A (ko) * 2022-08-02 2024-02-14 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4952515A (en) 1987-05-22 1990-08-28 Polymer Technology International Corp. Method of detection using a test strip having a non particulate dialyzed polymer layer
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
AU1411092A (en) 1991-01-31 1992-09-07 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
JP4860886B2 (ja) 2000-06-01 2012-01-25 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二本鎖パルボウイルスベクター
US20030181531A1 (en) 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003077796A2 (en) 2002-03-15 2003-09-25 University Of Southern California Ophthalmic solutions for delivery of expression vectors
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
EP1804835B9 (en) 2004-09-13 2010-09-29 Genzyme Corporation Multimeric constructs
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
DE102005020510A1 (de) 2005-04-29 2006-11-09 Basf Ag Verbundelement, insbesondere Fensterscheibe
US8216575B2 (en) * 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN101951925A (zh) * 2008-02-20 2011-01-19 建新公司 血管发生抑制
JP5425180B2 (ja) 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
CN102311502B (zh) * 2010-07-10 2013-12-25 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其医疗应用
MX2013006216A (es) * 2010-12-02 2013-10-17 Neurotech Usa Inc Lineas celulares que secretan andamios de anticuerpos anti-angionicos y receptores solubles y sus usos.
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
DK2968461T3 (da) 2013-03-13 2022-12-19 Genzyme Corp Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf

Also Published As

Publication number Publication date
CN105188733A (zh) 2015-12-23
US20220064262A1 (en) 2022-03-03
RU2015142999A (ru) 2017-04-17
PT2968461T (pt) 2022-12-26
IL266715A (en) 2019-07-31
HK1220618A1 (zh) 2017-05-12
EP2968461A1 (en) 2016-01-20
JP2016513669A (ja) 2016-05-16
US20170342127A1 (en) 2017-11-30
IL240950B (en) 2019-06-30
FI2968461T3 (fi) 2023-01-13
US9637534B2 (en) 2017-05-02
LT2968461T (lt) 2022-12-27
JP6561042B2 (ja) 2019-08-14
AR095437A1 (es) 2015-10-14
RU2692652C2 (ru) 2019-06-25
HUE060464T2 (hu) 2023-03-28
US10183983B2 (en) 2019-01-22
SG10201912956YA (en) 2020-02-27
MX363533B (es) 2019-03-27
SG11201506802SA (en) 2015-09-29
SI2968461T1 (sl) 2023-01-31
KR20150126923A (ko) 2015-11-13
EP2968461B1 (en) 2022-09-21
MX2015011951A (es) 2016-04-07
HRP20221447T1 (hr) 2023-01-20
AU2018278902A1 (en) 2019-01-03
WO2014160507A1 (en) 2014-10-02
ES2933558T3 (es) 2023-02-10
US20190345223A1 (en) 2019-11-14
JP2019123711A (ja) 2019-07-25
CN105188733B (zh) 2020-05-08
US20140315804A1 (en) 2014-10-23
AU2014243712B2 (en) 2018-09-13
RS63820B1 (sr) 2023-01-31
KR102228921B1 (ko) 2021-03-16
SG10201707501TA (en) 2017-10-30
UY35407A (es) 2014-10-31
IL240950A0 (en) 2015-11-30
US11084864B2 (en) 2021-08-10
AU2014243712A1 (en) 2015-10-15
TWI631133B (zh) 2018-08-01
BR112015022208A2 (pt) 2017-10-10
BR112015022208A8 (pt) 2018-01-23
PL2968461T3 (pl) 2023-01-30
CA2904623A1 (en) 2014-10-02
TW201506038A (zh) 2015-02-16

Similar Documents

Publication Publication Date Title
DK2968461T3 (da) Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf
DK3356413T3 (da) Anti-tigit-antigenbindingsproteiner og fremgangsmåder til anvendelse deraf
DK3280727T3 (da) Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK2999103T3 (da) Konverter og fremgangsmåde til styring deraf
DK3292141T3 (da) Fusionsproteiner
DK3275895T3 (da) Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
DK3017286T3 (da) Fremgangsmåde, kit og system til billeddannelse af en blodprøve
DK3107938T3 (da) Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
DK3744835T3 (da) Dna modificerende fusionsproteiner og metoder til anvendelse deraf
DK3581207T3 (da) Fusionsproteiner omfattende hoxd12 og nemo-bindingsdomæne og anvendelse deraf
DK3019533T3 (da) Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
DK2970464T3 (da) Anti-lag-3-bindende proteiner
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK3113797T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3083680T3 (da) Humaniserede anti-Tau(pS422)-antistoffer og fremgangsmåder til anvendelse
DK3697091T3 (da) Billedafkodningsindretning, billedafkodningsfremgangsmåde og billedafkodningsprogram
DK3265123T3 (da) Antistoffer, anvendelser og fremgangsmåder
DK3322734T3 (da) Multivalente og multispecifikke DR5-bindende fusionsproteiner
DK2894818T3 (da) Kontrolmetode i software-definerede netværk, styreanordning og processor
DK2983704T3 (da) Fusionspolypeptider og vacciner
DK3271453T3 (da) Glycosylerede lysosomale proteiner, fremgangsmåde til fremstilling og anvendelser
DK3380119T3 (da) Fmdv- og e2-fusionsproteiner og anvendelser deraf
DK3060922T3 (da) Fremgangsmåde og anordning til proteinfremstilling